1. Home
  2. INZY vs GCTS Comparison

INZY vs GCTS Comparison

Compare INZY & GCTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INZY
  • GCTS
  • Stock Information
  • Founded
  • INZY 2015
  • GCTS 1998
  • Country
  • INZY United States
  • GCTS United States
  • Employees
  • INZY N/A
  • GCTS N/A
  • Industry
  • INZY Biotechnology: Pharmaceutical Preparations
  • GCTS Blank Checks
  • Sector
  • INZY Health Care
  • GCTS Finance
  • Exchange
  • INZY Nasdaq
  • GCTS Nasdaq
  • Market Cap
  • INZY 64.9M
  • GCTS 69.0M
  • IPO Year
  • INZY 2020
  • GCTS N/A
  • Fundamental
  • Price
  • INZY $3.97
  • GCTS $1.03
  • Analyst Decision
  • INZY Buy
  • GCTS Strong Buy
  • Analyst Count
  • INZY 9
  • GCTS 1
  • Target Price
  • INZY $15.22
  • GCTS $5.00
  • AVG Volume (30 Days)
  • INZY 5.3M
  • GCTS 692.1K
  • Earning Date
  • INZY 05-14-2025
  • GCTS 05-14-2025
  • Dividend Yield
  • INZY N/A
  • GCTS N/A
  • EPS Growth
  • INZY N/A
  • GCTS N/A
  • EPS
  • INZY N/A
  • GCTS N/A
  • Revenue
  • INZY N/A
  • GCTS $6,359,000.00
  • Revenue This Year
  • INZY N/A
  • GCTS $315.43
  • Revenue Next Year
  • INZY N/A
  • GCTS $170.52
  • P/E Ratio
  • INZY N/A
  • GCTS N/A
  • Revenue Growth
  • INZY N/A
  • GCTS N/A
  • 52 Week Low
  • INZY $0.72
  • GCTS $1.01
  • 52 Week High
  • INZY $6.24
  • GCTS $5.65
  • Technical
  • Relative Strength Index (RSI)
  • INZY 85.93
  • GCTS 36.50
  • Support Level
  • INZY $3.94
  • GCTS $1.01
  • Resistance Level
  • INZY $3.97
  • GCTS $1.10
  • Average True Range (ATR)
  • INZY 0.08
  • GCTS 0.21
  • MACD
  • INZY 0.12
  • GCTS -0.03
  • Stochastic Oscillator
  • INZY 99.32
  • GCTS 1.37

About INZY Inozyme Pharma Inc.

Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.

About GCTS GCT Semiconductor Holding Inc. Common Stock

GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.

Share on Social Networks: